<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401581</url>
  </required_header>
  <id_info>
    <org_study_id>14-PP-07</org_study_id>
    <nct_id>NCT02401581</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours</brief_title>
  <acronym>PRECOCE</acronym>
  <official_title>Study ¨PRECOCE Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Benign hypertrophy of the prostate (BPH) is the most frequent pathology in the urinary tract
      of middle-aged men. In recent years, to enable BPH treatment with larger volumes and to
      reduce the risk of hemorrhage known to be associated to the transurethral resection of
      prostate treatment, transurethral photovaporisation of the prostate (PVP ) with the
      GreenLight (GL) XPS 180 W was developed. Therefore, the question arises to maximally reduce
      the length of catheterization to facilitate outpatient surgical management of prostate
      adenoma.

      In the investigators study, the investigators propose to evaluate the failure rate of an
      early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS
      in selected patients on general anesthesia or spinal anesthesia. To this end, the
      investigators realize a national multicenter prospective study including 300 patients. The
      effectiveness of this model of management is defined by absence of a need for
      re-catheterization in the post -operative period of 24 hours.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>failure rate of a limited catheterization duration of 3 hours post- operative</measure>
    <time_frame>at three hours post surgery</time_frame>
    <description>• The failure rate of a limited catheterization duration of 3 hours post- operative is defined by a need of recatheterizatrion within 24 hours post- GL with PVP XPS 180W . The catheterization remains indicated in case of macroscopic hematuria RAU or if no natural urination is possible</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose of energy</measure>
    <time_frame>during 24 hours hospitalisation</time_frame>
    <description>The total dose of energy delivered to the tissue induring the intervention will be expressed and collected by means of the instrumentation of the GL-XPS console.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of recatherization</measure>
    <time_frame>during 24 hours hospitalisation</time_frame>
    <description>The duration of recatherization is regarded as the total cumulative duration of catheterization regardless of the number of attempts for removale when it is a failure. The average duration of resondage counts only recatheterizations occurring in the first week which may be considered as due to PVP with GL XPS 180W followed by a shortened catheterization of 3 hours post- operatively . The duration of recatherization is defined from the time when it was done in thefirst week post- operative until urinary recovery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Benign Prostatic Hypertrophy</condition>
  <arm_group>
    <arm_group_label>rate of early removal of the catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In our study, we propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia for limiting autonomic effects on the bladder and ensure fastest possible recovery of voiding .</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Catheter</intervention_name>
    <description>The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).</description>
    <arm_group_label>rate of early removal of the catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients with lower urinary tract symptoms (LUTS )

          2. IPSS≥ 15 despite medical treatment &gt; 1 month if monotherapy or &gt; 3 months if
             bitherapie OR acute urinary retention ( RAU ) non-medical after the 1st failure to
             remove the catheter OR acute prostatitis OR macroscopic haematuria of prostatic origin

          3. prostate volume &gt; 30 cc by transrectal ultrasonography ;

          4. IPSS Qol ≥ 3 has at inclusion ;

          5. PSA ≤ 4 ng / ml ;

          6. if PSA between 4 and 10 then PSA L/T ≥25 % or negative PBP &lt;6 months .

          7. Accommodation &lt;50 km;

          8. company available for the return at home and monitoring first post- operative night .

          9. patient sign the informed consent

         10. patient covered by social security or other health insurance

        Exclusion criteria

          1. post- voiding residue &gt; 250 cc by suprapubic ultrasound not older than &lt; 45 days

          2. prostate volume &gt; 100 cc by transrectal ultrasound not older than 45 days

          3. urological antecedents : o urethral stenosis or cervical disease

               -  UTI in progress

               -  SAD patient or self-catheterization

               -  obstructive hydronephrosis + / - renal failure

               -  vesical calculi

               -  cancer of the prostate treated or untreated

               -  bladder tumor associated

               -  Interstitial cystitis ( symptom or biopsy)

          4. antecedent of the prostate surgery

          5. neurologic bladder ( parkinsonian syndrome , multiple sclerosis , lupus, neuropathy,
             Diabetic, cauda equina syndrome )

          6. criteria related concomitant medications that can not be stopped at least &lt; 48 hours
             before PVP with GL XPS 180 W

          7. contra indication for outpatient care for medical reason

          8. contra indication of a product analgesic according to protocol

          9. patient inability to understand and sign the informed consent as well as completing
             the questionnaires

         10. ASA Score &gt; 3 .
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DURAND Matthieu, Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Urologie, CHU de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DURAND Matthieu</last_name>
    <phone>+33492034011</phone>
    <email>durand.m@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Grasse - urologie</name>
      <address>
        <city>Grasse</city>
        <state>Alpes-maritimes</state>
        <zip>06130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colomb Frédéric, Ph</last_name>
      <email>colombfrederic@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Colomb Fréderic, Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Urologie</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DURAND Matthieu, Ph</last_name>
      <email>durand.m@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>Donzeau Dominique</last_name>
      <email>donzeau.d@chu-nice.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Durand Matthieu, Ph</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marseau Alexandre</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH privé St Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <state>Cote D'armor</state>
        <zip>22003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Della-Negra Emmanuel, PhD</last_name>
      <email>della-negra.emmanuel@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Della-Negra Emmanuel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Urologie Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornu Jean-Nicolas, Ph</last_name>
      <email>jncornu@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>Cornu Jean-Nicolas, Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Monsouris urologie</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barret Eric, Ph</last_name>
      <email>eric.barret@imm.fr</email>
    </contact>
    <investigator>
      <last_name>Barret Eric, Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Urologie - Hôpital Conception</name>
      <address>
        <city>Marseille</city>
        <state>Paca</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsenty Gilles, PhD</last_name>
      <email>gilles.karsenty@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Karsenty Gilles, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <state>Vendée</state>
        <zip>37 044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruyere Franck, PhD</last_name>
      <email>f.bruyere@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Bruyere Franck, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brest Urologie</name>
      <address>
        <city>Brest</city>
        <zip>2609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fournier Georges, PhD</last_name>
      <email>georges.fournier@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Fournier Georges, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thuillier Caroline, Ph</last_name>
      <email>CThuillier1@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Thuillier Caroline</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges -Urologie - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Descazeaud aurelien, PhD</last_name>
      <email>aureliendescazeaud@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Descazeaud Auréline, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique les Bleuets</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staerman Frédéric, Ph</last_name>
      <email>urologie.staerman@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Staerman Frederic, Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincendeau Sébastien, Phd</last_name>
      <email>sebastien.vincendeau@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Vincendeau Sébastien, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

